Chief Scientific Officer
Alzheimer’s Prevention Initiative, Banner Alzheimer’s Institute
Dr. Robert Alexander is the Chief Scientific Officer of the Alzheimer's Prevention Initiative, led by Banner Alzheimer's Institute.
In recent years, Dr. Alexander has focused on neurodegeneration in both Alzheimer’s and Parkinson’s disease. He also has extensive experience in both early- and late-stage drug development and medical governance.
Dr. Alexander was the medical leader of the AstraZeneca team that developed the beta-secretase inhibitor that delivered the phase 1 package and started phase 2/3 in only 21 months – the fastest development time in the class. Since then, he guided the early clinical development of a number of treatments targeted toward Alzheimer’s disease and other neurodegenerative disorders, including small molecules, antibodies, antisense oligomers and gene therapies.
Prior to joining the Banner Alzheimer’s Institute, Dr. Alexander was Vice President of the neuroscience therapeutic area unit at Takeda. He also worked for Pfizer as Vice President and Head of Clinical for the neuroscience and pain research unit. Additionally, Dr. Alexander was Vice President of Clinical for CNS and the Pain Innovative Medicines Unit (iMed) at AstraZeneca. His other prior leadership positions include Vice President and Head of Discovery Medicine and Chief Medical Officer of the Neurosciences Centre for Excellence in Drug Discovery at GlaxoSmithKline and Senior Director in the clinical neuroscience and clinical pharmacology at Merck Research Labs.
Dr. Alexander received his undergraduate and medical degrees from the University of Chicago. He completed an internal medicine internship at the New England Deaconess and a residency in Adult Psychiatry at McLean Hospital/Harvard Medical School. Following residency, Dr. Alexander was a fellow in the Neuropsychiatry Branch of National Institute of Mental Health (NIMH) and then at Columbia University (in Medical Genetics).